Astellas Pharma Community Letter

February 4, 2025: Astellas has made the difficult business decision to stop the development of ASP2016 – an investigational gene therapy to treat cardiomyopathy in adults living with FA. The decision is not due to any safety or efficacy concerns and there were no participants enrolled in the clinical trial.  This decision does not affect the other company’s rare disease gene therapy programs. Astellas is currently assessing potential options for its FA gene therapy compounds and will keep FARA informed as business discussions progress.  In addition, the company will investigate publishing it’s nonclinical FA work to share its learnings with FARA and the FA community.